Entities / Company
Innovent Biologics.
Chinese Biopharmaceutical Company
- Reports this week
- 1
- Active events
- 0
- Connections
- 17
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.Well supported4 reports2 developments inside
-
Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.Some support2 reports
One to three months ago
-
Innovent Biologics commercializes mazdutide for OPKO's license.Some support2 reports
-
Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.Some support2 reports
-
Innovent Biologics, a company based in China, focuses on global markets.Some support1 report
Gone quiet
No new reports in 90+ days-
Innovent Biologics and Definium Therapeutics, Inc. are biopharmaceutical companies currently competing for investment.Some support1 report
-
Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.Some support2 reports1 development inside
-
HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.Some support1 report
-
Ollin Biosciences is developing compounds (OLN102, OLN324) that target and challenge the market share of Amgen's Tepezza and Vabysmo.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Innovent Biologics this week
News at the entities that move Innovent Biologics most-
China StructuralEQT acquired majority share in Acronis, China upgraded smartphone surveillance tools, and a developer claimed performance improvements.Moves Innovent Biologics
-
Eli Lilly and Company OperationalMedicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Moves Innovent Biologics
-
Pfizer TransactionalBioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.Moves Innovent Biologics
Connections
The 5 strongest of 17, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Pfizer Transactional
Innovent Biologics and Pfizer entered a major partnership worth up to $10.5 billion, impacting financial guidance.
-
Eli Lilly and Company Operational
Innovent Biologics functions as a dedicated marketing and distribution partner for Eli Lilly and Company in the Chinese market.
-
China Structural
Innovent Biologics received regulatory approval for its drug Mazdutide in China.
-
Daiichi Sankyo Structural
Exclusive agreement for the commercialization and supply of Vanflyta.
-
Akeso Operational
Both companies are identified as key players and competitors within the Chinese biopharma sector.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
4 events- Innovent Biologics, a company based in China, focuses on global markets.
- Innovent Biologics and Definium Therapeutics, Inc. are biopharmaceutical companies currently competing for investment.
- Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.
- HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.
Show 1 earlier month
June 2026
3 events- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.
- Ollin Biosciences is developing compounds (OLN102, OLN324) that target and challenge the market share of Amgen's Tepezza and Vabysmo.